首页工具

登录

RANKL/TNFSF11/CD254 Protein, Human, Recombinant (hFc)

产品编号 TMPY-01471

别名: TRANCE, sOdf, CD254, hRANKL2, TNFSF11, ODF, OPTB2, tumor necrosis factor (ligand) superfamily, member 11, OPGL, RANKL

RANKL/TNFSF11/CD254 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 48.9 kDa and the accession number is AAC51762.1.

TargetMol的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

TargetMol

RANKL/TNFSF11/CD254 Protein, Human, Recombinant (hFc)

规格	价格/CNY		货期	数量
50 μg	￥ 2,440		5日内发货
500 μg	￥ 16,000		5日内发货

大包装超大折扣，点击咨询

更多批次查询请联系客服

生物活性

技术参数

产品性质

参考文献

生物活性	1. Measured by its binding ability in a functional ELISA. Immobilized human TNFRSF11B-His at 10 μg/ml (100 μl/well) can bind human Fc-TNFSF11 with a linear range of 3.125-200 ng/mL. 2. The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells. The ED50 for this effect is typically 7-35 ng/mL.
产品描述	RANKL/TNFSF11/CD254 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 48.9 kDa and the accession number is AAC51762.1.

种属	Human
表达系统	HEK293 Cells
标签	N-hFc
蛋白编号	AAC51762.1
别名	TRANCE, sOdf, CD254, hRANKL2, TNFSF11, ODF, OPTB2, tumor necrosis factor (ligand) superfamily, member 11, OPGL, RANKL
蛋白构建	The Human TNFSF11 (AAC51762.1) (Gly64-Asp245) was fused with the Fc region of Human IgG1 at the N-terminus.
蛋白纯度	> 86 % as determined by SDS-PAGE
分子量	48.9 kDa (predicted)

内毒素	< 1.0 EU/μg of the protein as determined by the LAL method.
缓冲液	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
复溶方法	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
存储	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice.
研究背景	Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein that belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

参考文献

1. Takayanagi H,et al.(2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 4 Suppl 3: S227-32. 2. Nakashima T,et al.(2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 15(3): 280-7. 3. Schwarz EM,et al.(2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther. 9 Suppl 1: S7. 4. Leibbrandt A,et al.(2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50.

计算器

复溶计算器

重组蛋白稀释计算器

比活力计算器

Volume (to add to vial)

=

Mass (in vial)

÷

Desired Reconstitution Concentration

bottom

技术支持

您可能有的问题的答案可以在重组蛋白操作手册中找到

Keywords

RANKL/TNFSF11/CD254 Protein, Human, Recombinant (hFc) OPTB-2 TRANCE sOdf TNFSF 11 TNFSF-11 CD254 hRANKL2 TNFSF11 ODF OPTB2 OPTB 2 CD 254 tumor necrosis factor (ligand) superfamily, member 11 OPGL CD-254 RANKL recombinant recombinant-proteins proteins protein

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

陶术

生物

TargetMol^®中国区唯一合作伙伴

点击进入陶术生物官网

陶术生物

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼